DOCSLIB.ORG

Drugs of Abuse (2017 Edition)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drugs of Abuse (2017 Edition) DrugsA DEA RESOURCE of Abuse GUIDE PRODUCED AND PUBLISHED BY Drug Enforcement Administration • U.S. Department of Justice WWW.DEA.GOV Contents Welcome ....................................................................... 7 VI. Depressants ........................................................... 56 I. Controlled Substances Act .......................................... 8 Barbiturates ........................................................................58 Drug Scheduling ................................................................15 Benzodiazepines ................................................................59 Schedule I ...........................................................................15 GHB.....................................................................................60 Schedule II ..........................................................................22 Rohypnol.............................................................................62 Schedule III .........................................................................24 VII. Hallucinogens ....................................................... 64 Schedule IV .........................................................................27 Ecstasy/MDMA ..................................................................66 Schedule V ..........................................................................29 Ketamine ............................................................................68 Federal Trafficking Penalties .............................................30 LSD ......................................................................................70 Federal Trafficking Penalties—Marijuana ........................31 Peyote & Mescaline ...........................................................71 II. U.S. Chemical Control ............................................. 32 Psilocybin ............................................................................72 Listed Chemicals Chart .....................................................34 VIII. Marijuana/Cannabis ............................................. 74 III. Introduction to Drug Classes .................................. 36 Marijuana Concentrates ....................................................76 IV. Narcotics ................................................................ 38 IX. Steroids ................................................................. 78 Fentanyl ..............................................................................40 X. Inhalants ................................................................. 80 Heroin .................................................................................42 XI. Drugs of Concern .................................................. 82 Hydromorphone ................................................................43 DXM ....................................................................................82 Methadone .........................................................................44 Kratom ................................................................................84 Morphine ............................................................................45 Salvia Divinorum ................................................................85 Opium .................................................................................46 XII. Designer Drugs ..................................................... 86 Oxycodone .........................................................................47 Bath Salts or Designer Cathinones ..................................86 V. Stimulants ............................................................... 48 K2 /Spice .............................................................................88 Amphetamines ...................................................................50 Synthetic Opioids ..............................................................90 Cocaine ...............................................................................51 XIII. Resources............................................................. 92 Khat .....................................................................................53 Methamphetamine ............................................................54 DRUGS OF ABUSE I 2017 EDITION: A DEA Resource Guide 5 Welcome TO THE LATEST EDITION OF DRUGS OF ABUSE Education plays a critical role in preventing substance abuse. Drugs of Abuse, A DEA Resource Guide, is designed to be a reliable resource on the most commonly abused and misused drugs in the United States. This comprehensive guide provides important information about the harms and consequences of drug use by describing a drug’s effects on the body and mind, overdose potential, origin, legal status, and other key facts. Drugs of Abuse also offers a list of additional drug education and prevention resources, including the DEA websites: www.DEA.gov; www.JustThinkTwice.com, aimed at teenagers; www.GetSmartAboutDrugs.com, designed for parents, educa- tors, and caregivers; and www.operationprevention.com. DRUGS OF ABUSE I 2017 EDITION: A DEA Resource Guide 7 I. Controlled Substances Act CONTROLLING DRUGS OR OTHER the Assistant Secretary for Health of HHS. SUBSTANCES THROUGH FORMAL The Assistant Secretary, by authority of the Secretary, compiles SCHEDULING the information and transmits back to the DEA: a medical and The Controlled Substances Act (CSA) places all substances scientific evaluation regarding the drug or other substance, a which were in some manner regulated under existing federal recommendation as to whether the drug should be controlled, law into one of five schedules. This placement is based upon and in what schedule it should be placed. the substance’s medical use, potential for abuse, and safety or The medical and scientific evaluations are binding on the DEA dependence liability. The Act also provides a mechanism for with respect to scientific and medical matters and form a part substances to be controlled (added to or transferred between of the scheduling decision. schedules) or decontrolled (removed from control). The Once the DEA has received the scientific and medical evalu- procedure for these actions is found in Section 201 of the Act ation from HHS, the Administrator will evaluate all available (21U.S.C. §811). data and make a final decision whether to propose that a drug Proceedings to add, delete, or change the schedule of a drug or other substance should be removed or controlled and into or other substance may be initiated by the Drug Enforce- which schedule it should be placed. ment Administration (DEA), the Department of Health and If a drug does not have a potential for abuse, it cannot be Human Services (HHS), or by petition from any interested controlled. Although the term “potential for abuse” is not party, including: defined in the CSA, there is much discussion of the term in the • The manufacturer of a drug legislative history of the Act. The following items are indicators • A medical society or association that a drug or other substance has a potential for abuse: • A pharmacy association (1) There is evidence that individuals are taking the drug or other substance in amounts sufficient to create a hazard • A public interest group concerned with drug abuse to their health or to the safety of other individuals or to • A state or local government agency the community. • An individual citizen (2) There is significant diversion of the drug or other sub- When a petition is received by the DEA, the agency begins its stance from legitimate drug channels. own investigation of the drug. The DEA also may begin an (3) Individuals are taking the drug or other substance on their investigation of a drug at any time based upon information own initiative rather than on the basis of medical advice from received from law enforcement laboratories, state and local a practitioner. law enforcement and regulatory agencies, or other sources (4) The drug is a new drug so related in its action to a drug or of information. other substance already listed as having a potential for abuse Once the DEA has collected the necessary data, the DEA to make it likely that the drug will have the same potential for Administrator, by authority of the Attorney General, requests abuse as such drugs, thus making it reasonable to assume from HHS a scientific and medical evaluation and recom- that there may be significant diversions from legitimate chan- mendation as to whether the drug or other substance should nels, significant use contrary to or without medical advice, or be controlled or removed from control. This request is sent to that it has a substantial capability of creating hazards to the 8 DRUGS OF ABUSE I A DEA Resource Guide: 2017 EDITION health of the user or to the safety of the community. Of course, by the CSA. They are as follows: evidence of actual abuse of a substance is indicative that a drug has a potential for abuse. Schedule I In determining into which schedule a drug or other substance • The drug or other substance has a high potential for abuse. should be placed, or whether a substance should be decontrolled • The drug or other substance has no currently accepted or rescheduled, certain factors are required to be considered. medical use in treatment in the United States. These factors are listed in Section 201 (c), [21 U.S.C. § 811 (c)] of • There is a lack of accepted safety for use of the drug or other the CSA as follows: substance under medical supervision. (1)The drug’s actual
Load more

Recommended publications
  • Hallucinogens - LSD, Peyote, Psilocybin, and PCP
    Hallucinogens - LSD, Peyote, Psilocybin, and PCP Hallucinogenic compounds found in some • Psilocybin (4-phosphoryloxy-N,N- plants and mushrooms (or their extracts) dimethyltryptamine) is obtained from have been used—mostly during religious certain types of mushrooms that are rituals—for centuries. Almost all indigenous to tropical and subtropical hallucinogens contain nitrogen and are regions of South America, Mexico, and classified as alkaloids. Many hallucinogens the United States. These mushrooms have chemical structures similar to those of typically contain less than 0.5 percent natural neurotransmitters (e.g., psilocybin plus trace amounts of acetylcholine-, serotonin-, or catecholamine- psilocin, another hallucinogenic like). While the exact mechanisms by which substance. hallucinogens exert their effects remain • PCP (phencyclidine) was developed in unclear, research suggests that these drugs the 1950s as an intravenous anesthetic. work, at least partially, by temporarily Its use has since been discontinued due interfering with neurotransmitter action or to serious adverse effects. by binding to their receptor sites. This DrugFacts will discuss four common types of How Are Hallucinogens Abused? hallucinogens: The very same characteristics that led to • LSD (d-lysergic acid diethylamide) is the incorporation of hallucinogens into one of the most potent mood-changing ritualistic or spiritual traditions have also chemicals. It was discovered in 1938 led to their propagation as drugs of abuse. and is manufactured from lysergic acid, Importantly, and unlike most other drugs, which is found in ergot, a fungus that the effects of hallucinogens are highly grows on rye and other grains. variable and unreliable, producing different • Peyote is a small, spineless cactus in effects in different people at different times.
    [Show full text]
  • Minnesota Statutes 1979 Supplement
    MINNESOTA STATUTES 1979 SUPPLEMENT 152.01 PROHIBITED DRUGS CHAPTER 152. PROHIBITED DRUGS Sec. 152.01 Definitions. 152.02 Schedules of controlled substances; admin­ istration of chapter. 152.01 Definitions. [For text of subds 1 to 8, see M.S.1978] Subd. 9. Marijuana. "Marijuana" means all parts of the plant of any species of the genus Cannabis, including all agronomical varieties, whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds or resin, but shall not include the mature stalks of such plant, fiber from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mix­ ture, or preparation of such mature stalks, except the resin extracted therefrom, fiber, oil, or cake, or the sterilized seed of such plant which is incapable of germination. [For text of subds 10 to 17, see M.S.1978] [ 1979 c 157 s 1 ] 152.02 Schedules of controlled substances; administration of chapter. [For text of subd 1, see M.S.1978) Subd. 2. The following items are listed in Schedule I: (1) Any of the following substances, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the exis­ tence of such isomers, esters, ethers and salts is possible within the specific chemical des­ ignation: Acetylmethadol; Allylprodine; Alphacetylmethadol; Alphameprodine; Alpham- ethadol; Benzethidine; Betacetylmethadol; Betameprodine; Betamethadol; Betaprodine; Clonitazene; Dextromoramide; Dextrorphan; Diampromide; Diethyliambutene; Dime- noxadol; Dimepheptanol; Dimethyliambutene; Dioxaphetyl butyrate; Dipipanone; Ethylmethylthiambutene; Etonitazene; Etoxeridine; Furethidine; Hydroxypethidine; Ke- tobemidone; Levomoramide; Levophenacylmorphan; Morpheridine; Noracymethadol; Norlevorphanol; Normethadone; Norpipanone; Phenadoxone; Phenampromide; Pheno- morphan; Phenoperidine; Piritramide; Proheptazine; Properidine; Racemoramide; Tri­ meperidine.
    [Show full text]
  • Did Internet-Purchased Diet Pills Cause Serotonin Syndrome?
    Did Internet-purchased diet pills cause serotonin syndrome? Phentermine also may have increased patient’s neuroleptic malignant syndrome risk s. G, age 28, presents to a tertiary® careDowden hospital Health Media with altered mental status. Six weeks ago she Mstarted taking phentermine, 37.5 mg/d, to lose weight. Her body mass indexCopyright is 24 kg/mFor2 (normal personal range), use only and she obtained the stimulant agent via the Internet. Her family reports Ms. G was very busy in the past week, staying up until 2 AM cleaning. They say she also was irritable with her 5-year-old son. Two days ago, Ms. G complained of fatigue and nausea without emesis. She went to bed early and did not awaken the next morning. Her sister found her in bed, minimally re- DIONISI sponsive to verbal stimuli, and brought her to the hospital. Patients have used phentermine as a weight-reducing IMAGES/SANDRA GETTY agent since the FDA approved this amphetamine-like © compound in 1960.1 Phentermine’s mechanism of ac- tion is thought to involve dopaminergic, noradrenergic, Kyoung Bin Im, MD and serotonergic effects.2 Stimulation of norepineph- Chief resident Internal medicine and psychiatry combined residency program rine (NE) release is its most potent effect, followed Departments of internal medicine and psychiatry by NE reuptake inhibition, stimulation of dopamine Jess G. Fiedorowicz, MD (DA) release, DA reuptake inhibition, stimulation of Associate in psychiatry serotonin (5-HT) release, and 5-HT reuptake inhibition Department of psychiatry (weak).3 Roy J. and Lucille A. Carver College of Medicine Because phentermine could in theory cause serotonin 4 University of Iowa syndrome, its use is contraindicated with monoamine Iowa City oxidase inhibitors (MAOIs) and not recommended with selective serotonin reuptake inhibitors (SSRIs).5 One case report describes an interaction between fl uox- etine and phentermine that appears consistent with se- rotonin syndrome.6 We are aware of no case reports of Current Psychiatry serotonin syndrome caused by phentermine alone.
    [Show full text]
  • Federal Register/Vol. 85, No. 36/Monday, February 24, 2020
    10466 Federal Register / Vol. 85, No. 36 / Monday, February 24, 2020 / Notices Controlled substance Drug code Schedule Alphamethadol ................................................................................................................................................................. 9605 I Benzethidine .................................................................................................................................................................... 9606 I Betacetylmethadol ........................................................................................................................................................... 9607 I Clonitazene ...................................................................................................................................................................... 9612 I Diampromide ................................................................................................................................................................... 9615 I Diethylthiambutene .......................................................................................................................................................... 9616 I Dimethylthiambutene ....................................................................................................................................................... 9619 I Ketobemidone .................................................................................................................................................................
    [Show full text]
  • Tobacco Labelling -.:: GEOCITIES.Ws
    Council Directive 89/622/EC concerning the labelling of tobacco products, as amended TAR AND NICOTINE CONTENTS OF THE CIGARETTES SOLD ON THE EUROPEAN MARKET AUSTRIA Brand Tar Yield Nicotine Yield Mg. Mg. List 1 A3 14.0 0.8 A3 Filter 11.0 0.6 Belvedere 11.0 0.8 Camel Filters 14.0 1.1 Camel Filters 100 13.0 1.1 Camel Lights 8.0 0.7 Casablanca 6.0 0.6 Casablanca Ultra 2.0 0.2 Corso 4.0 0.4 Da Capo 9.0 0.4 Dames 9.0 0.6 Dames Filter Box 9.0 0.6 Ernte 23 13.0 0.8 Falk 5.0 0.4 Flirt 14.0 0.9 Flirt Filter 11.0 0.6 Golden Smart 12.0 0.8 HB 13.0 0.9 HB 100 14.0 1.0 Hobby 11.0 0.8 Hobby Box 11.0 0.8 Hobby Extra 11.0 0.8 Johnny Filter 11.0 0.9 Jonny 14.0 1.0 Kent 10.0 0.8 Kim 8.0 0.6 Kim Superlights 4.0 0.4 Lord Extra 8.0 0.6 Lucky Strike 13.0 1.0 Lucky Strike Lights 9.0 0.7 Marlboro 13.0 0.9 Marlboro 100 14.0 1.0 Marlboro Lights 7.0 0.6 Malboro Medium 9.0 0.7 Maverick 11.0 0.8 Memphis Classic 11.0 0.8 Memphis Blue 12.0 0.8 Memphis International 13.0 1.0 Memphis International 100 14.0 1.0 Memphis Lights 7.0 0.6 Memphis Lights 100 9.0 0.7 Memphis Medium 9.0 0.6 Memphis Menthol 7.0 0.5 Men 11.0 0.9 Men Light 5.0 0.5 Milde Sorte 8.0 0.5 Milde Sorte 1 1.0 0.1 Milde Sorte 100 9.0 0.5 Milde Sorte Super 6.0 0.3 Milde Sorte Ultra 4.0 0.4 Parisienne Mild 8.0 0.7 Parisienne Super 11.0 0.9 Peter Stuyvesant 12.0 0.8 Philip Morris Super Lights 4.0 0.4 Ronson 13.0 1.1 Smart Export 10.0 0.8 Treff 14.0 0.9 Trend 5.0 0.2 Trussardi Light 100 6.0 0.5 United E 12.0 0.9 Winston 13.0 0.9 York 9.0 0.7 List 2 Auslese de luxe 1.0 0.1 Benson & Hedges 12.0 1.0 Camel 15.0 1.0
    [Show full text]
  • Molecular Modeling of Major Tobacco Alkaloids in Mainstream Cigarette Smoke Caren Kurgat, Joshua Kibet* and Peter Cheplogoi
    Kurgat et al. Chemistry Central Journal (2016) 10:43 DOI 10.1186/s13065-016-0189-5 RESEARCH ARTICLE Open Access Molecular modeling of major tobacco alkaloids in mainstream cigarette smoke Caren Kurgat, Joshua Kibet* and Peter Cheplogoi Abstract Background: Consensus of opinion in literature regarding tobacco research has shown that cigarette smoke can cause irreparable damage to the genetic material, cell injury, and general respiratory landscape. The alkaloid family of tobacco has been implicated is a series of ailments including addiction, mental illnesses, psychological disorders, and cancer. Accordingly, this contribution describes the mechanistic degradation of major tobacco alkaloids including the widely studied nicotine and two other alkaloids which have received little attention in literature. The principal focus is to understand their energetics, their environmental fate, and the formation of intermediates considered harmful to tobacco consumers. Method: The intermediate components believed to originate from tobacco alkaloids in mainstream cigarette smoke were determined using as gas-chromatography hyphenated to a mass spectrometer fitted with a mass selective detector (MSD) while the energetics of intermediates were conducted using the density functional theory framework (DFT/B3LYP) using the 6-31G basis set. Results: The density functional theory calculations conducted using B3LYP correlation function established that the scission of the phenyl C–C bond in nicotine and β-nicotyrine, and C–N phenyl bond in 3,5-dimethyl-1-phenylpyrazole were respectively 87.40, 118.24 and 121.38 kcal/mol. The major by-products from the thermal degradation of nicotine, β-nicotyrine and 3,5-dimethyl-1-phenylpyrazole during cigarette smoking are predicted theoretically to be pyridine, 3-methylpyridine, toluene, and benzene.
    [Show full text]
  • 2020 Kansas Statutes
    2020 Kansas Statutes 65-4105. Substances included in schedule I. (a) The controlled substances listed in this section are included in schedule I and the number set forth opposite each drug or substance is the DEA controlled substances code that has been assigned to it. (b) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation: (1) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- phenylacetamide) 9821 (2) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N- phenylacetamide) 9815 (3) Acetylmethadol 9601 (4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide; acryloylfentanyl) 9811 (5) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide) 9551 (6) Allylprodine 9602 (7) Alphacetylmethadol 9603(except levo-alphacetylmethadol also known as levo- alpha-acetylmethadol, levomethadyl acetate or LAAM) (8) Alphameprodine 9604 (9) Alphamethadol 9605 (10) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine) 9814 (11) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N- phenylpropanamide) 9832 (12) Benzethidine 9606 (13) Betacetylmethadol 9607 (14) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N- phenylpropanamide) 9830 (15) Beta-hydroxy-3-methylfentanyl (other
    [Show full text]
  • ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2019 (As of 10 January 2019 )
    ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2019 (as of 10 January 2019 ) Afghanistan Cannabis 50 Codeine 50 000 Cannabis resin 1 Dextropropoxyphene 10 000 Coca leaf 1 Diphenoxylate 5 000 Cocaine 15 Fentanyl 1 Codeine 650 000 Methadone 20 000 Codeine -N-oxide 1 Morphine 8 000 Dextromoramide 1 Pethidine 90 000 Dextropropoxyphene 200 000 Pholcodine 40 000 Difenoxin 1 Albania Dihydrocodeine 1 Cocaine 1 Diphenoxylate 1 Codeine 1 189 000 Dipipanone 1 Fentanyl 300 Ecgonine 2 Heroin 1 Ethylmorphine 1 Methadone 7 000 Etorphine 1 Morphine 7 800 Fentanyl 17 000 Oxycodone 2 000 Heroin 1 Pethidine 2 700 Hydrocodone 10 000 Pholcodine 1 500 Hydromorphone 4 000 Remifentanil 9 Ketobemidone 1 Sufentanil 2 Levorphanol 1 Algeria Methadone 100 000 Alfentanil 350 Morphine 1 550 000 Codeine 2 500 000 Morphine -N-oxide 1 Etorphine 1 Nicomorphine 1 Fentanyl 500 Norcodeine 1 Methadone 4 000 Normethadone 1 Morphine 9 000 Normorphine 1 Oxycodone 4 000 Opium 10 Pethidine 3 000 Oripavine 1 Pholcodine 1 500 000 Oxycodone 60 000 Remifentanil 1 Oxymorphone 1 Sufentanil 30 Pethidine 50 000 Andorra Phenoperidine 1 Cannabis 2 000 Pholcodine 1 Fentanyl 100 Piritramide 1 Methadone 1 000 Remifentanil 20 000 Morphine 500 Sufentanil 10 Oxycodone 2 000 Thebacon 1 Pethidine 500 Thebaine 70 000 Remifentanil 4 Tilidine 1 Angola Armenia Alfentanil 20 Codeine 3 000 Codeine 21 600 Fentanyl 40 Dextromoramide 188 Methadone 13 500 Dextropropoxyphene 200 Morphine 7 500 Dihydrocodeine 500 Thebaine 15 Diphenoxylate 300 Trimeperidine 1 500 Fentanyl 63 Aruba* Methadone 2 000
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with Regulation Joseph L
    Hofstra Law Review Volume 18 | Issue 3 Article 10 1990 A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with Regulation Joseph L. Galiber Follow this and additional works at: http://scholarlycommons.law.hofstra.edu/hlr Part of the Law Commons Recommended Citation Galiber, Joseph L. (1990) "A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with Regulation," Hofstra Law Review: Vol. 18: Iss. 3, Article 10. Available at: http://scholarlycommons.law.hofstra.edu/hlr/vol18/iss3/10 This document is brought to you for free and open access by Scholarly Commons at Hofstra Law. It has been accepted for inclusion in Hofstra Law Review by an authorized administrator of Scholarly Commons at Hofstra Law. For more information, please contact [email protected]. Galiber: A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with R A BILL TO REPEAL CRIMINAL DRUG LAWS: REPLACING PROHIBITION WITH REGULATION Joseph L. Galiber* Conventional wisdom obliges elected officials to beat the narcodrums loudly and incessantly, and to demand increasingly harsh criminal penalties for the sale and use of illegal drugs.' It is reasonable to wonder why I, a senator, would dare submit a bill2 to the New York State Legislature which would regulate all drugs cur- rently proscribed as illegal in precisely the same manner as alcohol.3 The short answer is that the use of the criminal law to control drug use has not, and never will, have anything more than a costly and marginal impact on drug consumption.4 Despite all the public hyperventilation, drug consumption remains a private, consensual * New York State Senator; B.A.
    [Show full text]
  • Federal Register/Vol. 85, No. 178/Monday, September 14, 2020
    Federal Register / Vol. 85, No. 178 / Monday, September 14, 2020 / Notices 56631 agreements. All non-confidential DEPARTMENT OF JUSTICE ADDRESSES: Written comments should written submissions will be available for be sent to: Drug Enforcement public inspection at the Office of the Drug Enforcement Administration Administration, Attention: DEA Federal Secretary and on EDIS. [Docket No. DEA–713] Register Representative/DPW, 8701 The Commission vote for these Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must determinations took place on September Importer of Controlled Substances Application: Cerilliant Corporation be sent to: Drug Enforcement 8, 2020. Administration, Attn: Administrator, The authority for the Commission’s AGENCY: Drug Enforcement 8701 Morrissette Drive, Springfield, determination is contained in section Administration, Justice. Virginia 22152. All request for a hearing 337 of the Tariff Act of 1930, as ACTION: Notice of application. should also be sent to: (1) Drug amended (19 U.S.C. 1337), and in Part SUMMARY: Cerilliant Corporation has Enforcement Administration, Attn: 210 of the Commission’s Rules of applied to be registered as an importer Hearing Clerk/OALJ, 8701 Morrissette Practice and Procedure (19 CFR part of basic class(es) of controlled Drive, Springfield, Virginia 22152; and 210). substance(s). Refer to Supplemental (2) Drug Enforcement Administration, Attn: DEA Federal Register By order of the Commission. Information listed below for further Representative/DPW, 8701 Morrissette Issued: September 8, 2020. drug information. DATES: Drive, Springfield, Virginia 22152. Lisa Barton, Registered bulk manufacturers of the affected basic class(es), and SUPPLEMENTARY INFORMATION: In Secretary to the Commission. applicants therefore, may file written accordance with 21 CFR 1301.34(a), this [FR Doc.
    [Show full text]
  • CONTROLLED SUBSTANCE, DRUG, DEVICE and COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun
    CONTROLLED SUBSTANCE, DRUG, DEVICE AND COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun. 23, 2011, P.L. 36, No. 7 Cl. 35 Session of 2011 No. 2011-7 SB 1006 AN ACT Amending the act of April 14, 1972 (P.L.233, No.64), entitled "An act relating to the manufacture, sale and possession of controlled substances, other drugs, devices and cosmetics; conferring powers on the courts and the secretary and Department of Health, and a newly created Pennsylvania Drug, Device and Cosmetic Board; establishing schedules of controlled substances; providing penalties; requiring registration of persons engaged in the drug trade and for the revocation or suspension of certain licenses and registrations; and repealing an act," further providing for Schedule I controlled substances. The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows: Section 1. Section 4(1) of the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, amended November 24, 1999 (P.L.894, No.55), is amended to read: Section 4. Schedules of Controlled Substances.--The following schedules include the controlled substances listed or to be listed by whatever official name, common or usual name, chemical name, or trade name designated. (1) Schedule I--In determining that a substance comes within this schedule, the secretary shall find: a high potential for abuse, no currently accepted medical use in the United States, and a lack of accepted safety for use under medical supervision. The following controlled substances are included in this schedule: (i) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation: 1.
    [Show full text]